Article
Lancet reports the results of the METHODS study from Australia where hand osteoarthritis (HOA) patients benefitted from 6 months of methotrexate (MTX) - as long as there was MRI synovitis!
All News
Dr. John Cush
Tweet
Rheumatologist Survey on PMR & steroid-sparing. What percentage of PMR pts do you use a steroid-sparing agent? Answer here: https://t.co/rIMzlyYZst
Dr. John Cush
Tweet
53.2 Million with Diagnosed Arthritis (USA: 2019–2021)
Last week the CDC's MMWR reports that during 2019–2021, 21.2% of U.S. adults (53.2 million) reported "diagnosed arthritis"
https://t.co/UKtR0q40cU https://t.co/9Wb1dAtzDJ
Dr. John Cush
Tweet
Curious about the latest updates in treating axSpA? Don't miss out on the RheumNow Therapeutic Update! This engaging video series explores the current recommendations from the ASAS-EULAR Guidelines. https://t.co/Zto7we8z6M https://t.co/TvXzsFUZ46
Dr. John Cush
Tweet
Innovative, full-read, state-of-the-art article on IMAGING in INFLAMMATORY ARTHRITIS & its future role in precision medicine. "Imaging is poised to become an invaluable tool in precision medicine..". HR-pQCT, 3T or 7T MRI, FAPI PET–CT, CEUS, FOI, etc https://t.co/JlZZf2KZdi https://t.co/eSpE9RAcvB
Dr. John Cush
Tweet
Canadian survey of 620 pts w/ chronic & debilitating arthritis, shows the majority (76%) are free of psychiatric disorders (76%) & in good (complete) mental health (56%); fostered by having a confidant, & being without insomnia, depression/anxiety https://t.co/6agOYCmnit https://t.co/IBKCjUo0DQ
Dr. John Cush
Tweet
Turkish study 1,134 PsA pts found mean Dx delay=35 mos (median: 12). 39% Dx w/in 3 mos, & 67% w/in 24 mos. Dx delay decr. over time: 60 to 24 mos (<2010 to 2015–2019). Dx delay factors: less education (OR 2.6), arthritis>PSO (1.7), LBP 1st (1.6)https://t.co/GYKPSaYWhU https://t.co/YYwaiQd5mJ
Dr. John Cush
Tweet
Tomorrow! Join us for #PMR & Steroid-Sparing Therapeutics featuring panelists Drs. Robert Spiera and Sarah Mackie, and moderator Dr. Sebastian Sattui .
https://t.co/UjtWAvSOXU https://t.co/LbZKybkAzK
Dr. John Cush
Tweet
FDA Approves IV Secukinumab
On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)
https://t.co/zv7b98ZUjS https://t.co/1rXjYIbLpw
Dr. John Cush
Tweet
Full Read review of #PMR in Lancet:
- Start @ 12·5–25mg prednisone qd
- Remission in most but, relapses in 40–60%
- Onset sudden; AM stiffness predominates; Shoulders>Pelvic
~50% have distal MSK Sxs
- US: look for B/L sub-acromial/deltoid bursitis https://t.co/0j1nRmdizP https://t.co/7cURm1pQeB
Dr. John Cush
Tweet
#PMR: glad or bad tidings?
Please don’t tell your patient that PMR “typically” lasts two years. Because it probably won’t last exactly two years, and then they’ll be less inclined to believe other things you say.
Read more...
https://t.co/UXuUzEVjFI
@sarah_L_mackie https://t.co/UnXsyuq4V4
Dr. John Cush
Tweet
Hepatotoxicity related to Anakinra has been reported in pediatric rheumatology patients. LFT elevations have been reported with IL-1 inhibition, even after excluding LFTs from the inflamm Dx, other drugs, MAS, etc. Here are 3 case reports. https://t.co/6ZxIcHbUEd https://t.co/Cx0kbn7JU2
Dr. John Cush
Tweet
FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/XiikNr3hWO https://t.co/Xd66zgvoDv
Dr. John Cush
Tweet
Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure
Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/c4mYjdLKW7 https://t.co/lXh5klx0cq
Dr. John Cush
Tweet
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
https://t.co/k5SAshxdsg https://t.co/tMtRHn2C6j
Dr. John Cush
Tweet
Registration is now open! Early bird pricing is available until 11/30/23. See you there!
https://t.co/zjXyldwlyl https://t.co/CpQ00745c1
Dr. John Cush
Tweet
#PMR: Is There Hidden GCA?
Dr. Anisha Dua, asks the question: in PMR should you worry about occult GCA?
https://t.co/Cd6u2GwJuo
@anisha_dua https://t.co/dWUH4zudPc
Dr. John Cush
Tweet
UK researchers develop a human vascularised synovium-on-a-chip: mechanically stimulated, 3D, microfluidic device w/ synovial cells and blood vessel cells to investigate syn inflammation & monocyte recruitment, mimics the forces applied w/ joint movement https://t.co/qlRHSE3o2b https://t.co/dsKvcsyysa
Dr. John Cush
Tweet
Turkish study 1,134 PsA pts found mean Dx delay=35 mos (median: 12). 39% Dx w/in 3 mos, & 67% w/in 24 mos. Dx delay decr. over time: 60 to 24 mos (<2010 to 2015–2019). Dx delay factors: less education (OR 2.6), arthritis>PSO (1.7), LBP 1st (1.6)https://t.co/q6aqtcaTxS https://t.co/uZSgoYuxJT
Dr. John Cush
Tweet
#PMR with Cancer
Dr. Sebastian Sattui (Pittsburgh, PA) Can PMR be a paraneoplastic presentation? QD Clinics are video vignettes with lessons from the clinic.
https://t.co/YhTkKpmzIl
@sattuiSEMD https://t.co/FTsz3QA5Cn
